LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung

被引：0

作者：

Wu, Yi-Long ^{[1
,2
]}

Zhou, Caicun ^{[3
]}

Hu, Cheng-Ping ^{[4
]}

Feng, Jifeng ^{[5
]}

Lu, Shun ^{[6
]}

Huang, Yunchao ^{[7
]}

Li, Wei ^{[8
]}

Hou, Mei ^{[9
]}

Shi, Jian Hua ^{[10
]}

Lee, Kye Young ^{[11
]}

Massey, Dan ^{[12
]}

Shi, Yang ^{[13
]}

Chen, JiongJie Jack ^{[13
]}

Zazulina, Victoria ^{[12
]}

Geater, Sarayut L. ^{[14
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China

[4] Cent S Univ, Xiangya Hosp, Dept Pulm Med, Changsha, Hunan, Peoples R China

[5] Jiangsu Prov Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai 200030, Peoples R China

[7] Kunming Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Yunnan Tumor Hosp, Kunming, Yunnan Province, Peoples R China

[8] Jilin Univ, Hosp 1, Ctr Canc, Changchun 130023, Peoples R China

[9] Sichuan Univ, West China Hosp, Chengdu 610064, Sichuan, Peoples R China

[10] Lin Yi Tumor Hosp, Linyi, Shandong, Peoples R China

[11] Konkuk Univ, Med Ctr, Lung Canc Ctr, Seoul, South Korea

[12] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[13] Boehringer Ingelheim Int Trading Shanghai Co Ltd, Shanghai, Peoples R China

[14] Prince Songkla Univ, Fac Med, Dept Internal Med, Div Resp & Resp Crit Care Med, Hat Yai, Thailand

来源：

EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷

关键词：

Lung cancer / Oncology;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

5470

引用

页数：2

共 50 条

[1] LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M plus ) advanced adenocarcinoma of the lung.
Wu, Yi Long
Zhou, Caicun
Hu, Cheng-Ping
Feng, Ji Feng
Lu, Shun
Huang, Yunchao
Li, Wei
Hou, Mei
Shi, Jian Hua
Lee, Kye Young
Massey, Dan
Shi, Yang
Chen, Jiongjie
Zazulina, Victoria
Geater, Sarayut Lucien
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
Hirsh, Vera
Park, Keunchil
Tan, Eng-Huat
Zhang, Li
O'Byrne, Kenneth
Boyer, Michael
Yang, James Chih-Hsin
Mok, Tony
Fan, Jean
Massey, Dan
Paz-Ares, Luis
EUROPEAN RESPIRATORY JOURNAL, 2016, 48
[3] LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
Schuler, Martin
Yang, James Chih-Hsin
Yamamoto, Nobuyuki
O'Byrne, Ken
Hirsh, Vera
Mok, Tony
Massey, Dan
Zazulina, Victoria
Shahidi, Mehdi
Sequist, Lecia
LUNG CANCER, 2012, 77 : S25 - S26
[4] LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE III STUDY OF AFATINIB VS. PEMETREXED AND CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG HARBORING EGFR ACTIVATING MUTATIONS
O'Byrne, Ken
Schuler, Martin
Yamamoto, Nobuyuki
Hirsh, Vera
Mok, Tony
Massey, Dan
Zazulina, Victoria
Shahidi, Mehdi
Sequist, Lecia
Yang, James
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S102 - S102
[5] LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE III STUDY OF AFATINIB VERSUS PEMETREXED AND CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG HARBOURING EGFR-ACTIVATING MUTATIONS
Boyer, M.
Schuler, M.
Yamamoto, N.
O'Byrne, K.
Hirsh, V
Mok, T.
Massey, D.
Zazulina, V
Shahidi, M.
Sequist, L.
Yang, J. C.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S161 - S161
[6] LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
Yang, James Chih-Hsin
Schuler, Martin H.
Yamamoto, Nobuyuki
O'Byrne, Kenneth John
Hirsh, Vera
Mok, Tony
Geater, Sarayut Lucien
Orlov, Sergey V.
Tsai, Chun-Ming
Boyer, Michael J.
Su, Wu-Chou
Bennouna, Jaafar
Kato, Terufumi
Gorbunova, Vera
Lee, Ki Hyeong
Shah, Riyaz N. H.
Massey, Dan
Lorence, Robert M.
Shahidi, Mehdi
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)
Sequist, L.
Schuler, M.
Yamamoto, N.
O'Byrne, K.
Hirsh, V.
Mok, T.
Massey, D.
Zazulina, V.
Shahidi, M.
Yang, J.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S203 - S203
[8] Symptom and Quality of Life Improvement in LUX-Lung 6 An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer
Geater, Sarayut L.
Xu, Chong-Rui
Zhou, Caicun
Hu, Cheng-Ping
Feng, Jifeng
Lu, Shun
Huang, Yunchao
Li, Wei
Hou, Mei
Shi, Jian Hua
Lee, Kye Young
Palmer, Michael
Shi, Yang
Lungershausen, Juliane
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 883 - 889
[9] First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
Schuler, M.
Paz-Ares, L.
Sequist, L. V.
Tan, E. H.
Mok, T.
Hirsh, V.
O'Byrne, K.
Zhang, L.
Yamamoto, N.
Boyer, M.
Shah, R.
Bennouna, J.
Dickgreber, N. J.
De Greve, J.
Love, J.
Maerten, A.
Fan, J.
Ehrnrooth, E.
Park, K.
Yang, J. C. H.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S176 - S177
[10] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Yi-Long
Zhou, Caicun
Hu, Cheng-Ping
Feng, Jifeng
Lu, Shun
Huang, Yunchao
Li, Wei
Hou, Mei
Shi, Jian Hua
Lee, Kye Young
Xu, Chong-Rui
Massey, Dan
Kim, Miyoung
Shi, Yang
Geater, Sarayut L.
LANCET ONCOLOGY, 2014, 15 (02): : 213 - 222

← 1 2 3 4 5 →